Free Trial

Scancell (LON:SCLP) Shares Up 29.8% - What's Next?

Scancell logo with Medical background

Scancell Holdings plc (LON:SCLP - Get Free Report) shot up 29.8% during trading on Monday . The company traded as high as GBX 11.38 ($0.15) and last traded at GBX 11 ($0.15). 10,537,342 shares changed hands during trading, an increase of 1,073% from the average session volume of 897,982 shares. The stock had previously closed at GBX 8.48 ($0.11).

Scancell Stock Performance

The stock has a market cap of £109.27 million, a PE ratio of -16.18 and a beta of 0.35. The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01. The business has a 50 day moving average price of GBX 8.58 and a two-hundred day moving average price of GBX 10.80.

Scancell (LON:SCLP - Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) EPS for the quarter. As a group, equities research analysts forecast that Scancell Holdings plc will post -2.5361112 EPS for the current fiscal year.

About Scancell

(Get Free Report)

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.

Featured Stories

Should You Invest $1,000 in Scancell Right Now?

Before you consider Scancell, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scancell wasn't on the list.

While Scancell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Buy the Fear: 3 Down Stocks That Could 10x Your Profits
Congress Bought THESE Stocks as Tariffs Tanked the Market
5 Stocks to BUY Now as Tariff Uncertainty Fades

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines